PYGL as a Novel Biomarker for Disease Progression and Prognosis in HEV-ALF Patients.

Authors

Siyu Feng, Mingzhi Pan, Luyu Wang, Changyi Ji, Ze Xiang, Jian Wu, Mengmeng Gu

Published in

Journal of medical virology. Volume 98. Issue 9. Pages e71126.

Abstract

Hepatitis E virus (HEV) is a significant cause of acute liver failure (ALF). The role of glycogen phosphorylase L (PYGL) in the diagnosis and prognosis of HEV-ALF remains unclear. This study collected clinical data and baseline characteristics from HEV-ALF patients, acute hepatitis E (AHE) patients, and healthy controls (HCs), measuring serum PYGL levels in each group. Methods including Orthogonal partial least squares discriminant analysis (OPLS-DA), receiver operating characteristic (ROC) and decision curve analysis (DCA) were used to evaluate the clinical utility of PYGL. Results showed that PYGL effectively diagnosed HEV-ALF (AUC = 0.911). PYGL levels were significantly higher in HEV-ALF patients than in AHE patients and HCs (p < 0.001). Among HEV-ALF patients, non-survivors exhibited higher PYGL levels than survivors (p < 0.001). PYGL demonstrated good predictive ability for 30-day mortality (AUC = 0.859). OPLS-DA and DCA confirmed its strong decision-making utility. Furthermore, PYGL levels escalated with increasing organ failure and paralleled clinical worsening, being highest in the deterioration group (p < 0.05). PYGL is a potential diagnostic and prognostic biomarker in HEV-ALF patients, where elevated levels indicate poorer outcomes and support early intervention.

PMID:
42683547
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.